|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
|
29272081 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Despite being a short duration study, albiglutide showed strong superiority for reduction in the major adverse CV events (MACE) composite in people with extant cardiovascular disease (CVD), in line with the earlier studies on the GLP-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide.
|
30607467 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RA reduced major cardiovascular events (MACE) by 13% (HR, 0.87; 95% CI, 0.80-0.96; P = 0.011) with a non-significant heterogeneity between subgroups of patients with and without cardiovascular disease (CVD) (P = 0.220).
|
31373167 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lately, GLP-1RAs have spiked the interest of researchers and clinicians due to their beneficial effects on CVD.
|
31825468 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are two pharmacological classes that have proven their efficacy to reduce major cardiovascular events (MACEs) in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease in large prospective cardiovascular outcome trials (CVOTs): EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), LEADER (liraglutide) and SUSTAIN 6 (semaglutide).
|
29944969 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we show that protection from cardiovascular disease in the absence of natural IELs depends on the enteroendocrine-derived incretin GLP-1<sup>2</sup>, which is normally controlled by IELs through expression of the GLP-1 receptor.
|
30700910 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite the early positioning of GLP-1RA in T2D treatment algorithms, GLP-1RA have been prescribed in patients with progressively more advanced disease stage and especially in the presence of cardiovascular disease.
|
31673896 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition to their effects on glycemic control, two specific classes of relatively new anti-diabetic drugs, namely the sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of major adverse cardiovascular events (MACE) in subjects with type 2 diabetes (T2D) at high risk for cardiovascular disease (CVD).
|
29886514 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas glucose control using classical glucose-lowering agents (except perhaps metformin) largely fails to reduce cardiovascular disease (CVD), two new pharmacological classes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter type 2 inhibitors (SGLT2is), have proven their ability to reduce major cardiovascular events in patients with established CVD.
|
31108136 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This article shares our consensus on clinical recommendations for the use of sodium-glucose co-transporter 2 inhibitors (SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) in people with Type 2 diabetes and established or at very high risk of cardiovascular disease in the UK.
|
31254356 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent trials with SGLT-2is and GLP-1RAs show superiority in CVD event reduction as opposed to only noninferiority.
|
29702499 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
GLP-1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
|
28407414 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RAs and SGLT2i are now advocated as second-line agents in European and US guidelines for management of both hyperglycaemia and for primary prevention of cardiovascular disease in people with T2DM.
|
31551292 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Large clinical trials have evaluated the cardiovascular effects of GLP-1RAs in patients with T2DM and elevated risk of cardiovascular disease and the results are very promising.
|
30545359 |
2018 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among them, 20 obese individuals with diabetes with inadequate glycemic control and metformin monotherapy received GLP-1Ra treatment for 3 months and were reassessed for metabolic, cognitive, olfactory, and neuroimaging changes.
|
31221697 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs are associated with a reduction in cardiovascular morbidity and mortality in high-risk patients with diabetes.
|
31595657 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to identify predictors of the efficacy of GLP-1ra on Hemoglobin A1c (HbA1c) in patients with insulin-independent diabetes.
|
30788807 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose co-transporter-2 (SGLT2) inhibitors and almost all glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown, beyond their effect on glucose control, to lead to a significant decrease in the cardiovascular burden of diabetes.
|
31209982 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As its glucose-lowering action is glucose dependent, a GLP-1 receptor agonist (GLP-1RA) achieves these benefits with a lower risk of hypoglycemia compared with other diabetes therapies.
|
28721686 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Findings on cardiovascular protection with sodium-glucose co-transporter 2 inhibitors (SGLT-2i) and some glucagon-like peptide 1 receptor agonists (GLP-1RA) support their use for older patients with diabetes.
|
30187176 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the safety of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), and its effects on body weight management in adults without diabetes.
|
31264757 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results with GLP1-receptor agonists (GLP-1RA) on microvascular complications of diabetes are contrasting.
|
28748377 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are desirable for diabetes, especially in patients with overweight/obesity.
|
29167470 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects.
|
29247356 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |